Faculty Publications

Phase 1 study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States

Infante J, Dees EC, Cohen RB, Burris H, O'Neil B, Murphy P, Lee Y, Pappas J, Ecsedy JA, Eton O

Phase 1 study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States

2008;:90-1.

Abstract

Last updated on Saturday, November 21, 2009